AlphAIAlphAI — Financial news for AI agents
massdevice.comOCT 222 min read$JNJ

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

Original reporting
massdevice.com
Published Oct 22, 2026, 2:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
J&J, Medtronic present pulsed field ablation data from global real-world use — source image
Source · massdevice.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The low complication rates and high procedural success could improve market perception of both companies' cardiac‑ablation pipelines and support future regulatory submissions.

02

Market read

First‑time real‑world data for pulsed‑field ablation platforms may drive modest price appreciation for JNJ and MDT.

03

What to watch

The devices are not yet FDA‑cleared in the US; U.S. market impact depends on future approvals.

Relevance 9/10Novelty 9/10Timing: same‑day conference release

Background

The article reports fresh clinical registry results presented at the Asia Pacific Heart Rhythm Society meeting, marking the first public disclosure of these data.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson presented first real‑world data for its Varipulse Pro and Omnypulse pulsed‑field ablation catheters, showing 100% procedural success and low complication rates.

Expected impact

likely modest upside as the market prices in the low‑complication data

Evidence & confidence

First‑time real‑world data with zero strokes or deaths is material for a medical‑device maker and can lift the stock ahead of upcoming regulatory filings.

$MDTBullishHigh confidence
Context

Medtronic disclosed registry results for its PulseSelect system and Affera/Sphere‑9 catheter, reporting 100% procedure success and very low major‑complication rates.

Expected impact

likely modest upside as investors absorb the favorable safety profile

Evidence & confidence

First real‑world registry data for these platforms is material and may improve outlook for future approvals and sales.

Market effects

Sector

May reinforce confidence in the cardiac‑ablation device sector and could lift peers.

Regional

Data presented in Asia Pacific may boost investor sentiment for US‑listed med‑tech firms with global footprints.

Global

Adds to the pipeline of minimally invasive cardiac therapies, a growing global market.

Counterpoint

What could challenge this read

If regulatory approval timelines slip, the data may not translate into near‑term revenue, limiting upside.

Key entities

  • Company
    Johnson & Johnson MedTech

    US‑listed medical‑device division of J&J, ticker JNJ.

  • Company
    Medtronic

    US‑listed medical‑device maker, ticker MDT.

Read at source← All news

StoryJohnson & Johnson unveils positive 12‑month results for its pulsed field ablation platforms at APHRS 2026

Also covered by

5 outlets

Related articles

OCT 22
$JNJMedAI 8/10

J&J Reports New Data on Atrial Fibrillation Devices

Johnson & Johnson presented new clinical data for its atrial fibrillation devices at the Asia Pacific Heart Rhythm Society 2026 meeting. The Varipure device showed 100% acute procedural success in 225 patients, while 82.5% of 136 Omnypulse patients had no recurrence after 12 months.

ocbj.com2 min
OCT 22
$JNJMedAI 8/10

Why is Johnson & Johnson stock rallying today?

Johnson & Johnson (JNJ) stock rose 3.0% after presenting positive clinical data for its pulsed field ablation technology at a conference. The VARIPURE and Omny-IRE studies showed high success rates and low adverse events. Analysts raised price targets, with Wells Fargo setting a new target of $287. Despite a broader market decline, JNJ's stock gained due to its defensive appeal and strong pharmaceutical segment growth.

investing.com2 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Presents Breakthrough Atrial Fibrillation Stud

Johnson & Johnson (JNJ) presented positive clinical trial results for atrial fibrillation treatments at a conference. The VARIPURE study showed 100% procedural success, while Omny-IRE achieved 82.5% success in preventing arrhythmia recurrence. JNJ has a 2.06% dividend yield, 70% payout ratio, and 4.9% dividend growth over three years. The stock trades 32.5% above its GF Value™, with insiders selling $150.7M in shares over the past year.

gurufocus.com3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro Platform showed 100% acute procedural success, 0.4% adverse event rate, and 17.9-minute mean ablation time. OMNYPULSE Platform had 82.5% freedom from arrhythmia recurrence at 12 months. Both studies support JNJ's atrial fibrillation treatment technologies.

finanznachrichten.de3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platfor

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro showed 100% acute procedural success in 225 patients, with a 0.4% adverse event rate. OMNYPULSE Platform had 82.5% freedom from AF recurrence at 12 months. CARTO 3 System data showed lower long-term AF-related acute-care utilization compared to EnSite.

gurufocus.com2 min
OCT 22
$JNJMedAI 8/10

J&J reports clinical data on pulsed field ablation platforms

Johnson & Johnson (JNJ) presented clinical data from two studies on its pulsed field ablation platforms at a conference in South Korea. The VARIPURE study reported 100% acute procedural success with minimal adverse events. The Omny-IRE study showed 82.5% of patients free from atrial arrhythmia recurrence at 12 months. Both studies were published in medical journals.

investing.com2 min